DuPont initiates Sustiva oral liquid expanded access program.
D000284:Administration, Oral; D000293:Adolescent; D000480:Alkynes; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D048588:Benzoxazines; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003521:Cyclopropanes; D004345:Drug Industry; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D015337:Multicenter Studies as Topic; D010078:Oxazines / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; C098320:efavirenz